Compare · DVA vs MGRX
DVA vs MGRX
Side-by-side comparison of DaVita Inc. (DVA) and Mangoceuticals Inc. (MGRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DVA and MGRX operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- DVA is the larger of the two at $15.17B, about 1627.5x MGRX ($9.3M).
- Over the past year, DVA is up 62.1% and MGRX is down 67.1% - DVA leads by 129.2 points.
- Both names hit the wire about 1 times in the past 4 weeks.
- DVA has more recent analyst coverage (13 ratings vs 0 for MGRX).
- Company
- DaVita Inc.
- Mangoceuticals Inc.
- Price
- $235.59+0.11%
- $0.57+5.09%
- Market cap
- $15.17B
- $9.3M
- 1M return
- +10.42%
- +54.93%
- 1Y return
- +62.08%
- -67.15%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 1
- 1
- Recent ratings
- 13
- 0
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Latest DVA
- DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call
- Chief Legal & Pub. Affairs Off Waters Kathleen Alyce sold $3,210,377 worth of shares (15,405 units at $208.40) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 109,194 units (SEC Form 4)
- Chief Executive Officer Rodriguez Javier sold $14,532,108 worth of shares (69,407 units at $209.38), decreasing direct ownership by 8% to 840,408 units (SEC Form 4)
- SEC Form 11-K filed by DaVita Inc.
- DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Yale Phyllis R gifted 5,038 shares, decreasing direct ownership by 35% to 9,525 units (SEC Form 4)
- Director Pullin Dennis W was granted 250 shares, increasing direct ownership by 10% to 2,671 units (SEC Form 4)
- Director Schoppert Wendy Lee was granted 250 shares (SEC Form 4)
- Director Moore Gregory J. was granted 250 shares, increasing direct ownership by 3% to 7,813 units (SEC Form 4)
- Director Arway Pamela M was granted 250 shares, increasing direct ownership by 0.94% to 26,945 units (SEC Form 4)
Latest MGRX
- SEC Form S-8 filed by Mangoceuticals Inc.
- Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 10-Q filed by Mangoceuticals Inc.
- SEC Form NT 10-Q filed by Mangoceuticals Inc.
- SEC Form 10-K filed by Mangoceuticals Inc.
- SEC Form NT 10-K filed by Mangoceuticals Inc.
- SEC Form 4 filed by Cohen Jacob D.
- SEC Form 4 filed by Cohen Jacob D.
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.